Valuation: InspireMD

Market Cap 34.7M 30.01M 28.03M 25.71M 48.36M 3.3B 49.13M 329M 129M 1.66B 130M 127M 5.47B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 34.7M 30.01M 28.03M 25.71M 48.36M 3.3B 49.13M 329M 129M 1.66B 130M 127M 5.47B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 1.58x
Free-Float
73.48%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2020
Director of Finance/CFO 58 25/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 02/06/2017
Director/Board Member 68 07/02/2013
Director/Board Member 62 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 34.7M
+0.47%+4.09%-9.92%+18.43% 130B
+1.37%-3.93%-17.22%-0.67% 12.63B
+5.28%+7.98%+104.57%+139.45% 10.61B
+2.59%-3.43%-43.52%-67.91% 4.7B
+2.93%+3.12%-22.39%+42.74% 2.7B
+2.16%+19.82%-21.92%-77.34% 1.74B
+2.82%+0.80%-14.07%-12.55% 1.69B
+2.16%-0.93%-31.19%-27.86% 1.66B
Average +1.77%+3.66%-6.96%+1.79% 20.72B
Weighted average by Cap. +1.00%+3.66%-4.68%+20.89%

Financials

2026 *2027 *
Net sales 10.38M 8.97M 8.38M 7.69M 14.46M 987M 14.69M 98.33M 38.59M 495M 38.96M 38.11M 1.64B 21.92M 18.96M 17.7M 16.24M 30.54M 2.09B 31.03M 208M 81.52M 1.05B 82.3M 80.5M 3.46B
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-